Overview of First-Line Treatment Options in EGFR-Mutant NSCLC

This segment frames the current first-line treatment landscape for EGFR-mutant metastatic non–small cell lung cancer and how it has evolved over two decades. The discussion contrasts historic “pill only” approaches with today’s more complex decision-making, where multiple active regimens now compete in the frontline setting. Key options reviewed include a chemotherapy plus osimertinib strategy (FLAURA2-type), a non‑chemotherapy combination of a bispecific antibody targeting EGFR and MET plus a TKI (Mariposa-type), and osimertinib monotherapy as the established third-generation TKI standard. The speakers emphasize that current goals extend beyond rapid responses to durable systemic and CNS control and delay of resistance. The importance of comprehensive molecular testing to identify EGFR mutations is underscored as the critical entry point for this treatment pathway. This episode orients viewers to the core regimens and sets up later case-based discussions on how efficacy, tolerability, and patient preferences drive regimen selection.